C

Cambridge Cardiac Care Centre | Cambridge, Canada

Research site
(Unclaimed)
Location
150 Hespeler Road, Cambridge, Ontario, Canada

Site insights

Top conditions

Top treatments

Semaglutide
Ziltivekimab
Bococizumab
Etripamil
LY3298176
BELVIQ
Survodutide
Triglycerides
vitamin K
Pemafibrate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 24 total trials

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (ATHENA)

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either...

Enrolling
Systemic Inflammation
Heart Failure
Drug: Placebo
Drug: Ziltivekimab
Locations recently updated

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fract...

Enrolling
Heart Failure With Preserved Ejection Fraction
Heart Failure
Drug: Placebo
Drug: LY3540378

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have ab...

Enrolling
Myocardial Infarction
Sudden Death
Other: Usual care
Device: Implantable Cardioverter Defibrillator + Usual Care

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on to...

Active, not recruiting
Chronic Kidney Disease
Drug: Matching placebo
Drug: Empagliflozin
Locations recently updated

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: MK-0616

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran
Locations recently updated

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide
Locations recently updated

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Novo Nordisk logo
Amgen logo
Boehringer Ingelheim logo
Lilly logo
M
Pfizer logo
C
Eisai logo
Kowa logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems